Related Experiment Video
Updated: Dec 21, 2025
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
510
Long-Term Outcomes With Teduglutide From a Single Center.
Frances Puello1, Elizabeth Wall2, Jean Herlitz2
1Department of Internal Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
JPEN. Journal of Parenteral and Enteral Nutrition
|May 12, 2020
Summary
Teduglutide therapy significantly reduces parenteral support needs in short-bowel syndrome patients over several years. Many achieve substantial reductions, with some discontinuing support entirely.
Area of Science:
- Gastroenterology
- Clinical Pharmacology
- Patient Outcomes
Background:
- Short-bowel syndrome (SBS) is a complex condition requiring long-term management.
- Parenteral support (PS) is a common treatment for SBS, but carries significant risks.
- Teduglutide is a therapeutic agent investigated for improving outcomes in SBS patients.
Purpose of the Study:
- To quantify the long-term clinical outcomes of teduglutide treatment in patients with short-bowel syndrome (SBS).
- To assess the sustained efficacy of teduglutide in reducing the need for parenteral support (PS).
Main Methods:
- A retrospective, single-center study was conducted.
- Data were collected from patients who started teduglutide between March 2013 and May 2019.
- Eighteen patients were included in the final analysis with a median follow-up of 3.2 years.
Main Results:
- A high percentage of patients showed a response ( >20% reduction in PS) at multiple time points: 75% at 12 months, 76.9% at 24 months, 70% at 36 months, and 100% at 60 months.
- Five patients (28%) achieved freedom from PS, with four discontinuing by 6 months.
- Factors like colon-in-continuity or ileocecal valve presence did not significantly affect response rates.
Conclusions:
- Teduglutide therapy demonstrates rapid and sustained reductions in PS requirements in a real-world SBS patient cohort.
- Further postmarketing studies are needed to identify predictors of treatment response and factors contributing to enteral autonomy.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
741
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
741
01:16Insulin: Dosing Regimen and Adverse Effects
574
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
574
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
183
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
183
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
164
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
164
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
348
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
348